Edit
Angiocrine Bioscience, Inc.
https://angiocrinebioscience.com/Last activity: 12.03.2021
Probably Closed
Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $15M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Cobro Vent... | cobroventu... |
| - | Good Growt... | goodgrowth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2022 | Grant | $15M | - |
Mentions in press and media 4
| Date | Title | Description |
| 12.03.2021 | Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation | |
| 05.02.2021 | Angiocrine Bioscience Announces Oral Presentation of Intravenous AB-205 Data during the Annual Transplantation & Cellular Therapy Meetings of ASCT and CIBMTR | |
| 04.12.2020 | Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 62nd Annual Meeting of the American Society of Hematology (ASH) | |
| - | Angiocrine Bioscience | “Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs” |